Eur Rev Med Pharmacol Sci 2019; 23 (13): 5667-5674

DOI: 10.26355/eurrev_201907_18303

MiR-203 inhibits the malignant behavior of prostate cancer cells by targeting RGS17

L.-S. Zhang, H.-G. Ma, F.-H. Sun, W.-C. Zhao, G. Li

Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China. gangli@suda.edu.cn


OBJECTIVE: The aim of this study was to explore the role of microRNA-203 (miR-203) in Prostate Cancer (PCa), and to further verify its influence in PCa cell function.

PATIENTS AND METHODS: The expression level of miR-203 in 55 clinical PCa cases and cell lines was detected by qRT-PCR. Then, the target gene of miR-203 in PCa cells was predicted and verified by online prediction software and Luciferase reporter gene assay, respectively. Furthermore, the role of miR-203 in PCa cell proliferation, colony formation, cell cycle and metastasis capacities was detected through a series of in vitro experiments.

RESULTS: The expression of miR-203 in PCa tissues and cells was significantly reduced when compared with that of normal tissues and cells. In searching for potential downstream targets of miR-203, a regulator of G-protein signaling 17 (RGS17) entered our sight due to its active role in a variety of malignant tumors. More importantly, the negative regulation of RGS17 by miR-203 was verified by Luciferase reporter gene assay. Functional experiments demonstrated that low expression of RGS17 in PCa cells induced by up-regulation of miR-203 could significantly restrain the proliferation, invasion and migration capacities of PCa cells.

CONCLUSIONS: MiR-203 served as a tumor suppressor gene in PCa. Through targeting RGS17, miR-203 significantly controlled the malignant behavior of PCa cells. Our findings revealed that miR-203/RGS17 axis might be a potential therapeutic target for the treatment of PCa.

Free PDF Download

To cite this article

L.-S. Zhang, H.-G. Ma, F.-H. Sun, W.-C. Zhao, G. Li
MiR-203 inhibits the malignant behavior of prostate cancer cells by targeting RGS17

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 13
Pages: 5667-5674
DOI: 10.26355/eurrev_201907_18303